Tags : SEQUOIA Study

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study

Vartika Singh October 16, 2019

Shots: The P-III SEQUOIA study involves assessing of Pegilodecakin + Folfox (folinic acid, 5-FU, oxaliplatin) vs Folfox as monothx. in 567 patients with metastatic adenocarcinoma of the pancreas with diseases […]readmore

Tags : SEQUOIA Study

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : SEQUOIA Study

Lilly Reports Results Pegilodecakin + Folfox in P-III SEQUOIA Study

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company